The REVERT Randomized Controlled Trial demonstrated the superiority of the modified valsalva maneuver (MVM) over the standard valsalva maneuver in re-establishing normal sinus rhythm in patients with Paroxysmal SVT. MVM exaggerates venous return to the heart and increases vagal outflow by elevating the patient's legs. However, the success rate of the MVM is still significantly lower than that of intravenous adenosine, the first-line pharmacological therapy for treating PSVT, which establishes NSR by transiently slowing electrical conduction through the AV node.

Given that these two treatment options operate via different physiologic mechanisms, could MVM and IV adenosine be combined synergistically to convert PSVT with better success rates than either treatment individually and with better safety profiles?